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Abstract
TGF-β-induced endothelial-to-mesenchymal transition (EndoMT) is a newly recognized
source of profibrotic activated myofibroblasts and has been suggested to play a role in the
pathogenesis of various fibrotic processes. Endothelin-1 (ET-1) has been implicated in the
development of tissue fibrosis but its participation in TGF-β-induced EndoMT has not been
studied. Here we evaluated the role of ET-1 on TGF-β1-induced EndoMT in immunopurified
CD31+/CD102+ murine lung microvascular endothelial cells. The expression levels of α-
smooth muscle actin (α-SMA), of relevant profibrotic genes, and of various transcription fac-
tors involved in the EndoMT process were assessed employing quantitative RT-PCR,
immunofluorescence histology and Western blot analysis. TGF-β1 caused potent induction
of EndoMT whereas ET-1 alone had a minimal effect. However, ET-1 potentiated TGF-β1-
induced EndoMT and TGF-β1-stimulated expression of mesenchymal cell specific and pro-
fibrotic genes and proteins. ET-1 also induced expression of the TGF-β receptor 1 and 2
genes, suggesting a plausible autocrine mechanism to potentiate TGF-β-mediated EndoMT
and fibrosis. Stimulation of TGF-β1-induced skin and lung fibrosis by ET-1 was confirmed in
vivo in an animal model of TGF-β1-induced tissue fibrosis. These results suggest a novel
role for ET-1 in the establishment and progression of tissue fibrosis.
Introduction
Activated myofibroblasts comprise a unique population of mesenchymal cells that play a cru-
cial role in the development of pathologic fibrotic processes and are considered to be the ulti-
mate effector cells in various fibrotic disorders including Systemic Sclerosis (SSc), Idiopathic
Pulmonary Fibrosis (IPF), and cardiac, liver and kidney fibrosis [1,2]. These cells express high
levels of α-smooth muscle actin (α-SMA) and display a remarkable pro-fibrotic phenotype
with increased production of numerous extracellular matrix (ECM) macromolecules
PLOSONE | DOI:10.1371/journal.pone.0161988 September 1, 2016 1 / 21
a11111
OPEN ACCESS
Citation:Wermuth PJ, Li Z, Mendoza FA, Jimenez
SA (2016) Stimulation of Transforming Growth
Factor-β1-Induced Endothelial-To-Mesenchymal
Transition and Tissue Fibrosis by Endothelin-1 (ET-
1): A Novel Profibrotic Effect of ET-1. PLoS ONE
11(9): e0161988. doi:10.1371/journal.pone.0161988
Editor: Philip C. Trackman, Boston University Henry
M Goldman School of Dental Medicine, UNITED
STATES
Received: May 3, 2016
Accepted: August 16, 2016
Published: September 1, 2016
Copyright: © 2016 Wermuth et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: Funded by AR19616 National Institutes of
Health www.nih.gov SAJ. The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
including type I and type III collagens. Owing to their crucial role in the pathogenesis of tissue
fibrosis and various fibrotic diseases there has been intense investigation of their cellular ori-
gins [3,4]. These studies have shown that myofibroblasts arise from various sources including
resident quiescent fibroblasts [4,5], bone marrow-derived fibrocytes [6–8] and epithelial cells
undergoing epithelial to mesenchymal transition (EMT) [9–11]. More recently, it has also
been demonstrated that endothelial cells are capable of acquiring a mesenchymal phenotype
through endothelial to mesenchymal transition or EndoMT [12]. Although the occurrence of
EndoMT has been well documented during vertebrate cardiac embryonic development [12],
its post-developmental occurrence was not accepted until numerous recent studies demon-
strated EndoMT in various experimental animal models of fibrosis and in various human
fibrotic diseases [13–15]. Indeed, EndoMT has been shown to occur in organ-specific fibrotic
disorders including cardiac, kidney, and intestinal fibrosis [16–21], in cancer-associated fibro-
sis [22], and in Systemic Sclerosis (SSc)-associated pulmonary fibrosis and Pulmonary Arterial
Hypertension (PAH) as well as in Primary PAH [23–26].
TGF-β is a member of a large family of multifunctional polypeptide growth factors
involved in the regulation of a broad array of biological and physiological processes [27,28].
TGF-β signaling results in a potent stimulation of expression of a large number of pro-fibrotic
genes and in a marked increase in the production of their corresponding proteins [27–29] and
has been shown to play a major role in the development of tissue fibrosis in numerous organ-
specific and systemic human fibrotic diseases including SSc [30–32]. Recent studies have
shown that besides its effects on the expression of pro-fibrotic genes TGF-β pro-fibrotic effects
may also be mediated through its key role in the initiation and regulation of EndoMT [13–15,
17, 33–35].
Endothelin-1 (ET-1), is a potent vasoconstrictor polypeptide produced and secreted by
endothelial cells [36,37]. ET-1 plays a crucial role in the pathophysiology of PAH and is a
prime therapeutic target for PAH and related group of disorders [38,39]. Besides its vascular
effects, numerous studies have described a variety of ET-1 profibrogenic activities including
stimulation of the synthesis of types I and III collagens, inhibition of the production of matrix
degrading metalloproteinases, stimulation of EMT, and induction of expression of profibro-
genic cytokines and growth factors such as connective tissue growth factor [40–46]. Further-
more, various human fibrotic diseases have been shown to display increased production of ET-
1 [47–49]. However, the role of ET-1 in EndoMT induction or in TGF-β-induced EndoMT has
not been studied extensively. One study [50] showed that endothelial cell-derived ET-1 pro-
motes cardiac fibrosis and heart failure in diabetic hearts through stimulation of EndoMT, and
a more recent study employing immunopurified CD31+ dermal endothelial cells from SSc
patients showed that TGF-β and ET-1 induced EndoMT in normal and SSc endothelial cells,
that these effects involved the Smad pathway, and that they were blocked by the specific ET-1
receptor antagonist, macitentan [26].
The purpose of the studies described here was to examine the interactions between ET-1
and TGF-β1 in the induction of EndoMT in murine lung microvascular endothelial cells and
to identify changes in expression levels of various relevant genes participating in EndoMT
modulation. These studies showed that ET-1 caused a strong potentiation of TGF-β1-induced
EndoMT in vitro. We further present in vivo results confirming the potentiation of TGF-
β1-induced tissue fibrosis in a murine animal model of fibrosis. Collectively, these results pro-
vide strong experimental evidence supporting a novel mechanism for the profibrotic effects of
ET-1 and suggest that inhibition of ET-1 activity during the earliest stages of development of
fibrotic processes when EndoMT plays an important role may represent a potent and effective
antifibrotic approach.
ET-1 Stimulates TGF-β1-Induced EndoMT
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Methods
Materials
Complete endothelial cell culture medium consisting of basal ECM supplemented with 5%
FBS, 10% endothelial cell growth supplement, 100 U/mL penicillin and 100 μg/mL streptomy-
cin was purchased from ScienCell Research Laboratories (Carlsbad, CA). Anti-CD31 and anti-
CD102 antibodies were purchased from BD Biosciences (Bedford, MA) and fetal bovine serum
(FBS) from Atlanta Biological (Lawrenceville, GA). The anti-α-SMA and anti-GAPDH anti-
bodies were fromMillipore (Billerica, MA). TGF-β1 was from Peprotech (Rocky Hill, NJ), and
ET-1 was from R&D Systems (Minneapolis, MN). Bosentan was purchased from Selleck
Chemicals (Houston, TX) and was resuspended in DMSO before use.
Isolation of Murine Pulmonary Endothelial Cells
Pulmonary microvascular endothelial cells were isolated from 8–12 week-old C57BL6/J mice
(Jackson Laboratories, Bar Harbor, ME; generation F25) with a modification of the method of
Marelli-Berg et al. [51] as described previously [52,53]. The procedures employed for isolation
of murine endothelial cells were approved by the Thomas Jefferson University Institutional
Animal Care and Use Committee and performed in accordance with National Institutes of
Health guidelines. Briefly, murine lungs were harvested, minced, and enzymatically digested
with collagenase (30 mg/100ml in 0.1% BSA, Worthington, Lakewood, NJ) to obtain a single
cell suspension. Endothelial cells were immunoselected with rat anti-mouse CD31 antibody
followed by magnetic bead separation using goat anti-rat IgG-conjugated microbeads (1:5, Mil-
tenyi Biotec, Auburn, CA, USA). The isolated endothelial cells were cultured in complete endo-
thelial cell culture medium on 2% gelatin pre-coated tissue culture dishes for 3–5 days.
Following expansion, the cells were resuspended and a second immunologic separation was
carried out using rat anti-mouse CD102 antibody as described [52,53]. The resulting CD31+/
CD102+ cells were plated and the endothelial cell phenotype of the preparation was confirmed
by evaluating cellular uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlo-
rate (DiI)-acetylated LDL (DiI-AcLDL, Biomedical Technologies, Stoughton, MA) and assess-
ment of cell morphology as described [52,53]. The proportion of spindle-shaped mesenchymal
cells relative to polygonal-shaped endothelial cells was assessed employing the Cell Counter.jar
plugin for NIH ImageJ software as described [54]. Cells with a diameter at their longest axis
that was two-fold greater than the average diameter of untreated cobblestone endothelial cells
were considered spindle-shaped.
Culture and Treatment of Murine Lung Microvascular Endothelial, Cells
with TGF-β1, ET-1, and Bosentan
The immunopurified murine lung microvascular endothelial cells were washed with serum-
free medium and then incubated with either TGF-β1 (10 ng/mL), or ET-1 (100 ng/mL), or
TGF-β1 plus ET-1 in FBS-depleted (0.5% FBS) endothelial cell culture medium. To confirm
the effects of ET-1, parallel samples were also pretreated with the dual ET-1 receptor antago-
nist, Bosentan (10 μM) for 3 h, after which the medium was replaced with fresh endothelial cell
culture medium containing 0.5% FBS and either ET-1 plus Bosentan or TGF-β1 plus ET-1 plus
Bosentan. The media were changed at 24 h with media containing fresh additives. On day 3 the
cells were harvested and total RNA and cellular proteins were isolated for subsequent studies.
Cytotoxicity and effects on cellular proliferation were assessed by incubating cells plated at
equal density prior to the initiation of treatment with the tetrazolium salt WST-1 (Roche Diag-
nostics, Indianapolis, IN) for 2 h at 37°C in a CO2 incubator and measuring the absorbance at
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a wavelength of 450 nm. Differences in absorbance levels reflect increases or decreases in cell
numbers mediated by changes in cellular proliferation and/or cytotoxicity effects.
Immunofluorescence Staining
Murine lung microvascular endothelial cells were seeded onto glass culture slides and treated
as described above. Following treatment, the cells were fixed with 3.7% formaldehyde and per-
meabilized with 0.1% Triton X-100 in PBS for 3 min. Slides were washed with PBS and blocked
with PBS containing 1% BSA at room temperature for 1 h, and then they were incubated with
primary antibodies against α-SMA (1:200). Slides were then incubated with Cy3-conjugated
secondary antibodies (1:500) followed by 4,6-diamidino-2-phenylindole (DAPI) (Jackson
ImmunoResearch Laboratories, West Grove, PA) for nuclear staining.
Western Blot Analysis
The cells were washed with cold PBS, harvested with a cell lifter, centrifuged and lysed with
RIPA lysis buffer (25 mM Tris-HCl pH 7.6, 150 mMNaCl, 1% NP-40, 1% Na deoxycholate
and 0.1% SDS) supplemented with a complete protease inhibitor cocktail (Roche Diagnostics,
Indianapolis IN), homogenized with a pellet pestle motor (Kimble/Kontes, Vineland, NJ) and
subsequently centrifuged at 13,000 x g for 15 min at 4°C. For Western blots either aliquots of
culture media containing the proteins secreted by the cultured cells or aliquots of the cell
lysates containing cellular proteins were resolved by SDS-polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA). Blots were blocked
for 1 h in Tris-buffered saline(TBS)-Tween (10 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl,
0.1% Tween 20) containing 5% nonfat dry milk (BioRad, Hercules, CA). The membranes were
then incubated overnight at 4°C with mouse monoclonal α-SMA antibody (Abcam, 1:200),
and GAPDH polyclonal rabbit antibody (Abcam, 1:2000) in a 5% nonfat dry milk/TBS-Tween
solution. Membranes were then washed with TBS-Tween, and incubated for 1 h with the
appropriate horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, UK)
diluted 3000-fold in 5% nonfat dry milk/TBS-Tween. The signals were quantified using NIH
Image J software.
Quantitative Reverse Transcription (RT)-PCR
Murine lung microvascular endothelial cells were cultured and treated as described above in
duplicate wells of 12 well gelatin-treated plastic tissue culture dishes for 72 h. Following treat-
ment, the cells were harvested with a cell lifter, washed in cold PBS, and processed for RNA
extraction (RNeasy kit; Qiagen, Valencia, CA) including a genomic DNA digestion step. Total
RNA (1 μg) was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen) to
generate first strand cDNA and various transcript levels were quantified using SYBR Green
real time PCR. The primers employed are listed in S1 Table. The differences in the number of
mRNA copies in each PCR were corrected for Gapdh endogenous control transcript levels; lev-
els in control experiments were set at 100 and all other values were expressed as multiples of
control values.
In Vivo Animal Studies and Histopathology Analysis
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Committee on the Ethics of Animal Experiments of Thomas Jefferson Univer-
sity (Protocol Number 01629). All surgery was performed under sodium pentobarbital
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anesthesia and all efforts were made to minimize suffering. Four week old FVB/N mice pur-
chased from The Jackson Laboratory were anesthetized and implanted subcutaneously on the
interscapular region with 28 day Alzet osmotic pumps containing either saline, or 2.5 μg TGF-
β1 alone, or 5 μg ET-1 alone, or 2.5 μg TGF-β1 plus 5 μg ET-1. Two animals were used per
treatment group. Mice were sacrificed three weeks post-implantation. After sacrifice, the hair
was removed with a commercial depilatory and a full thickness skin sample was surgically
excised from the interscapular region of the animals. The skin was stretched and pinned in his-
topathology cassettes and fixed in phosphate buffered formalin for 24 h. The lungs were
removed and the left lung was fixed by perfusion of the left pulmonary artery with paraformal-
dehyde for histopathological analyses. Paraffin embedded skin and lungs were stained with
hematoxylin-eosin or with Masson's trichrome according to standard procedures. Dermal
thickness was measured in hematoxylin-eosin stained sections viewed under 40X microscopic
examination by measuring the distance between the epidermal-dermal junction and the der-
mal-adipose layer junction at five randomly selected fields from one sample from each animal.
Immunohistochemical Analysis of Skin and Lung Tissues
Paraffin-embedded sections of skin and lung from animals treated with saline, TGF-β1, ET-1,
or with TGF-β1 plus ET-1 were deparaffinized and dehydrated following antigen retrieval with
a citric acid buffer, as described previously [53]. Slides were first incubated with blocking IgG
solution for 1 h, and then incubated overnight with anti–α-SMA (Abcam; 1:100 dilution) and
anti-von Willebrand antibodies (anti-vWF Dako; 1:50 dilution). IgG binding was revealed fol-
lowing incubation with an F(ab0) sheep anti-rabbit Cy3 antibody and an F(ab0) sheep anti-
mouse fluorescein isothiocyanate—conjugated antibody (Sigma) for 1h. Nuclei were counter-
stained with DAPI (Jackson ImmunoResearch). Samples were examined with a Zeiss 51 confo-
cal laser microscope to evaluate the colocalization of immunoreactivity.
Measurement of Collagen Content of Skin and Lung Tissues
The collagen content in the lungs and skin of the same animals sacrificed for the histopathology
studies was determined employing hydroxyproline assays as previously described [55]. Skin
samples were obtained from areas of skin adjacent to those used for histopathology employing a
4mm diameter tissue punch and the right lung was removed. The tissues were weighed and
hydrolyzed in 6MHCl overnight at 110°C. For determination of hydroxyproline content, two
separate aliquots of each sample were assayed in duplicate as described previously [55].
Statistical Analysis
Values are the mean and standard deviation of separate experiments each performed in tripli-
cate except for the hydroxyproline assays that were performed in two separate samples and
each sample was assayed in duplicate. The statistical significance of all data was assessed by
Student’s two-tailed t test. P values less than 0.05 were considered statistically significant.
Results
ET-1 Potentiates TGF-β1-Induced Expression of α-SMA in Murine Lung
Microvascular Endothelial Cells
We examined here the possibility that ET-1 may participate in the fibrotic process through
potentiation of TGF-β1-induced EndoMT in immunopurified murine lung microvascular
endothelial cells. The procedure for the isolation and culture of lung microvascular endothelial
cells yielded a highly homogenous population of cells with typical morphologic characteristics
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of endothelial cells in culture. To assess the induction of EndoMT, we evaluated endothelial
cell morphology and the expression of α-SMA, a marker of activated myofibroblasts. Saline-
treated endothelial cells predominantly displayed the characteristic polygonal cobblestone
morphology (Control in Fig 1A, top left), whereas treatment with TGF-β1 alone induced a
transition to a more spindle-shaped fibroblast-like morphology (TGF-β1 in Fig 1A, bottom
Fig 1. Effects of TGF-β1, or ET-1, or TGF-β1 plus ET-1 onmurine lungmicrovascular endothelial cell
morphology (A) andmyofibroblast generation (B). (A). Morphology. Murine lung microvascular
endothelial cells were cultured under control conditions (Control) or were treated with TGF-β1 (TGF-β1), ET-
1 (ET-1) or TGF-β1 plus ET-1 (TGF-β1+ET1) for 72 h. Following treatment the cultures were examined by
phase contrast microscope. The relative proportion of spindle-shaped cells was determined using NIH
ImageJ software. Magnification: 20X. (B).Myofibroblast generation. Murine lung microvascular endothelial
cells were grown and treated on chamber slides for 72 h and then fixed and immunostained with antibodies to
α-SMA. Cells were cultured under control conditions (Control) or were treated with TGF-β1 alone (TGF-β1),
ET-1 alone (ET-1) or a combination of TGF-β1 plus ET-1 (T+E). Note that ET-1 alone did not induce
significant changes in α-SMA expression but it markedly increased α-SMA expression induced by TGF-β1.
Magnification: 40X.
doi:10.1371/journal.pone.0161988.g001
ET-1 Stimulates TGF-β1-Induced EndoMT
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left) with 35 +/- 8% of the cells displaying this spindle-shaped morphology. ET-1 alone pro-
duced a lesser effect on endothelial cell morphology, inducing only 18 +/- 3% of the cells to
assume the fibroblast-like spindle shape (ET-1 in Fig 1A, top right). In contrast, ET-1 in combi-
nation with TGF-β1 resulted in a nearly complete loss of the cobblestone morphology and the
majority (85 +/-10%) of the cells acquired a spindle-shaped morphology (TGF-β1 plusET1 in
Fig 1A, bottom right). The changes in cellular morphology correlated with a change in the
expression of α-SMA. Saline-treated cells did not exhibit detectable expression of α-SMA
(Control in Fig 1B, top left), whereas TGF-β1 treatment alone induced potent EndoMT conver-
sion as evidenced by the appearance of numerous cells displaying strong α-SMA staining
(TGF-β1 in Fig 1B, bottom left). The data also revealed that ET-1 alone had no effect on α-
SMA expression (ET-1 in Fig 1B, top right), however, it displayed a potentiating effect on
TGF-β1-induced α-SMA expression as evidenced by a greater intensity of fluorescence in cul-
tures treated with ET-1 plus TGF-β1 (TGF-β1 plusET1 in Fig 1A, bottom right) in comparison
with cultures treated with TGF-β1 alone. These observations were confirmed by a quantitative
assessment of the proportion of cells expressing α-SMA in cultures exposed to TGF-β1 alone
compared to cultures treated with TGF-β1 plus ET-1. In the cultures treated with TGF-β1
alone about 27% of cells expressed α-SMA compared with 52% in the cultures treated with
both TGF-β1 plus ET-1 (compare TGF-β1 with T+E panels in Fig 1B). In all in vitro experi-
ments, there were no significant effects of TGF-β1 or ET-1 alone or in combination on cellular
proliferation and no cytotoxicity was detected using the WST-1 assay (data not shown).
Quantitation of α-SMA gene expression and protein levels present in lung microvascular
endothelial cell lysates analysed by RT-PCR and Western blot are shown in Fig 2. The Western
blot results demonstrated that untreated endothelial cells did not contain detectable α-SMA
levels and treatment with TGF-β1 caused an approximate 20-fold increase in α-SMA protein
levels (Fig 2A). Treatment of the cells with ET-1 alone failed to induce any detectable levels of
α-SMA, however, the simultaneous treatment of the cells with ET-1 and TGF-β1 resulted in a
nearly 30-fold increase in α-SMA protein levels compared to either the untreated endothelial
cells or to endothelial cells exposed to ET-1 alone (Fig 2A). Analysis of changes in expression
levels of Acta2, the gene encoding α-SMA, by semi-quantitative RT-PCR revealed a similar
effect of ET-1 on TGF-β1-mediated EndoMT, with TGF-β1 inducing a nearly 5-fold increase
in Acta2 expression whereas ET-1 alone did not have a significant effect (Fig 2B). In contrast,
ET-1 enhanced TGF-β1-mediated Acta2 expression to 15-fold compared to saline treated
endothelial cells. This increase was abolished by exposure of TGF-β1 plus ET-1-treated lung
microvascular endothelial cells to Bosentan, an inhibitor of ET-1 receptors A and B, indicating
that ET-1 was indeed responsible for the increase in Acta2 expression in samples treated with
TGF-β1 plus ET-1 compared to the levels observed in samples treated with TGF-β1 alone.
ET-1 Enhances the Expression of Types I and III Collagen during TGF-
β1-Induced EndoMT
Another effect of TGF-β-mediated EndoMT is an increase in the expression of the mesenchy-
mal-specific fibrillar type I and type III collagens (Col1a1 and Col3a1, respectively). Western
blot assessment showed that TGF-β1 induced a nearly 30-fold increase in levels of type I colla-
gen (COL1) present in the culture supernatants compared to saline-treated cells and that ET-1
treatment alone induced a minor but significant 2.5 fold increase in the levels of COL1 in these
cells (Fig 3A). In contrast, TGF-β1 in combination with ET-1 induced a nearly 45-fold increase
in COL1 levels. Fig 3B and 3C show the effects of TGF-β1 alone, ET-1 alone, or ET-1 plus
TGF-β1 on Col1a1 and Col3a1 gene expression. TGF-β1 alone induced a 3-fold increase in
Col1a1 expression (Fig 3B) and a 7-fold increase in Col3a1 expression (Fig 3C) whereas ET-1
ET-1 Stimulates TGF-β1-Induced EndoMT
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alone did not significantly alter the expression levels of either gene compared to those mea-
sured in saline-treated endothelial cells. ET-1 in combination with TGF-β1, however, increased
the levels of Col1a1 and Col3a1 expression to 5-fold and ~40-fold, respectively, compared to
levels in saline treated cells. Bosentan abrogated the stimulation of ET-1 on the TGF-β1-effects
on Col1a1 and Col3a1 expression.
Fig 2. Effects of TGF-β1, or ET-1, or TGF-β1 plus ET-1 on α-SMA protein levels and Acta2 gene
expression in cultured murine lung microvascular endothelial cells. (A). α-SMA protein levels. The
upper panel shows aWestern blot of cell lysates from the same samples shown in Fig 1B probed with α-
SMA (upper bands). GAPDH was used as loading control (lower bands). The Bottom panel shows a
quantitative densitometry of α-SMA analyzed using NIH Image J software. (B). Acta2 expression.
Expression levels of Acta2 determined by semiquantitative RT-PCR. Values represent the mean
(+/- standard deviation) expression levels of three replicates of three separate experiments. C(t) values
were normalized with Gapdh. The saline control levels were arbitrarily set at 100% expression. Values for
other samples are expressed relative to the saline control. Statistical significance was determined by
Student’s two-tailed t test. ***: p<0.001.
doi:10.1371/journal.pone.0161988.g002
ET-1 Stimulates TGF-β1-Induced EndoMT
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ET-1 Potentiates TGF-β1-Induced Increased Expression of
Mesenchymal Cell-Specific Transcription Factors
It was previously shown that TGF-β induced a marked increase in the expression of transcrip-
tion factors and transcription factor coactivators involved in EndoMT [33–35]. The results
Fig 3. Effects of TGF-β1, or ET-1, or TGF-β1 plus ET-1 on the expression of fibrillar type I and type III
collagens in murine lungmicrovascular endothelial cells.Murine lung endothelial cells were treated with
either TGF-β1, or ET-1, or Bosentan, or with TGF-β1 plus ET-1, or with TGF-β1 plus ET-1 plus Bosentan for
72 h. (A). The upper panel shows aWestern blot of culture supernatants probed with a Col1 primary antibody.
The bottom panel shows a quantitative densitometry of bands corresponding to COL1 analyzed using NIH
Image J software. (B,C). Expression levels of Col1a1 (B), andCol3a1 (C) as determined by semiquantitative
RT-PCR. Values represent the mean (+/- standard deviation) expression levels of three replicates of three
separate experiments. C(t) values were normalized withGapdh. The saline control levels were arbitrarily set
at 100% expression. Values for other samples are expressed relative to the saline control. Statistical
significance was determined by Student’s two-tailed t test. **: p < 0.01; ***: p<0.001. T: TGF-β1; E: ET-1; B:
Bosentan.
doi:10.1371/journal.pone.0161988.g003
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obtained here confirmed these studies as it was found that the levels of Snai1 in TGF-β1-treated
cells were ~15-fold greater than those measured in untreated endothelial cells (Fig 4A), the lev-
els of Snai2 were ~2.5-fold greater (Fig 4B), and the levels of Twist1 were ~5-fold greater (Fig
4C). Treatment with ET-1 alone did not significantly affect expression of any these genes,
whereas ET-1 potentiated TGF-β1-mediated increases in expression of Snai1 (to ~25-fold),
Snai2 (to ~4-fold) and Twist1 (to ~8-fold). Consistent with these observations, pretreatment of
Fig 4. Effects of TGF-β1, or ET-1, or TGF-β1 plus ET-1 on the expression of mesenchymal cell-
specific transcription factors in murine lung microvascular endothelial cells.Murine lung
microvascular endothelial cells were treated with either TGF-β1, or ET-1, or bosentan, or with TGF-β1 plus
ET-1, or with TGF-β1 plus ET-1 plus Bosentan for 72 h. Expression levels of Snai1(A), Snai2 (B) and Twist1
(C) were determined by semiquantitative RT-PCR. Values represent the mean (+/- standard deviation)
expression levels of three replicates of three separate experiments. C(t) values were normalized with
Gapdh. The saline control levels were arbitrarily set at 100% expression. Values for other samples are
expressed relative to the saline control. Statistical significance was determined by Student’s two-tailed t
test. **: p < 0.01; ***: p<0.001.
doi:10.1371/journal.pone.0161988.g004
ET-1 Stimulates TGF-β1-Induced EndoMT
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endothelial cells with Bosentan abrogated the ET-1-mediated increases in Snai1, Snai2 and
Twist1 expression, returning their expression levels to those observed with TGF-β1 treatment
alone.
ET-1 Enhances Expression of TGF-βGenes during TGF-β1-Mediated
EndoMT
To gain insight into the mechanisms responsible for the potentiating effects of ET-1 on TGF-
β1-induced EndoMT, we examined the effect of ET-1 on the expression levels of the TGF-β iso-
forms, Tgfb1, Tgfb2 and Tgfb3. Either TGF-β1 or ET-1 significantly increased expression of
Tgfb1 (Fig 5A) and of Tgfb2 (Fig 5B). However, ET-1 potentiated TGF-β1-mediated increases
in Tgfb1 and Tgfb2, inducing a 4-fold increase for either of these genes compared to untreated
cells. Although neither TGF-β1 alone nor ET-1 alone caused a significant change in the expres-
sion of Tgfb3, the combination of TGF-β1 plus ET-1 significantly increased expression of Tgfb3
by 2-fold (Fig 5C). Bosentan abrogated ET-1 plus TGF-β1-mediated increases in expression of
all TGF-β isoforms.
ET-1 Induces Expression of TGF-β Receptor Genes during TGF-β-
Mediated EndoMT
In these studies, we assessed the effects of TGF- β1, ET-1, or TGF-β1 plus ET-1 on the expres-
sion levels of three TGF-β receptors (Fig 6). Treatment with TGF-β1 alone had no significant
effect on the expression of Tgfbr1 and Tgfbr2 (Fig 6A and 6B) but induced a 2-fold increase
in Tgfbr3 (Fig 6C), whereas ET-1 alone significantly induced increased expression of all three
genes (6-fold for Tgfbr, 5-fold for Tgfbr2 and 7-fold for Tgfbr3) compared to saline treated
controls. However, in contrast with the other experiments reported here, no additional stim-
ulatory effects were observed when endothelial cells were exposed to the combination of
TGF-β1 and ET-1. Exposure to Bosentan suppressed all ET-1-mediated increases in TGF-β
receptor genes.
ET-1 Stimulates TGF-β1-Induced Skin and Lung Fibrosis In Vivo
These studies were performed to validate in vivo the results obtained in the in vitro studies indi-
cating that ET-1 stimulated the pro-fibrotic effects of TGF-β. Four week old FVB/N mice were
implanted subcutaneously with osmotic pumps containing either saline, or TGF-β1, or ET-1,
or TGF-β1 plus ET-1. Mice were sacrificed 3 weeks post-implantation and a sample of skin was
removed. Both lungs were also isolated. Trichrome staining of these tissues is displayed in Fig
7. The skin samples from mice implanted with pumps containing TGF-β1 revealed a nearly 2
fold increase in dermal thickness compared to the saline-treated animals (Fig 7, upper row).
The TGF-β1-treated skin also displayed mild to moderate multifocal to coalescing fibrosis of
the dermis and of the panniculus carnosum muscle. Increased collagen accumulation was also
demonstrated in the deeper dermis as well as surrounding numerous blood vessels in the skin
(Fig 7, second row). Mice treated with ET-1 alone exhibited minimal changes in dermal thick-
ness (Fig 7, upper row) and in the deep dermal histology (Fig 7, second row). In contrast, in
mice treated with TGF-β1 plus ET-1, the skin showed extensive dermal and hypodermal accu-
mulation of dense connective tissue with marked fibroplasia (Fig 7, top and middle rows), and
a 3.1 fold increase in dermal thickness.
The histopathology of the lungs is shown at low magnification in Fig 7, third row with
higher 10X magnification in Fig 7, bottom row. The lungs of the TGF-β1-treated mice dis-
played perivascular, peribronchiolar and interstitial fibrosis that was not evident in saline-
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treated animals as well as numerous areas of fibrotic consolidation whereas the lungs from the
ET-1-treated animals showed only a minimal increase in trichrome staining compared to lungs
isolated from the saline-treated control animals (Fig 7, bottom row). The lungs of mice treated
with TGF-β1 plus ET-1 displayed marked perivascular, peribronchiolar and severe interstitial
fibrosis with large areas of parenchymal replacement by fibrotic tissue (Fig 7, third and bottom
rows) compared to the untreated control and to ET-1 alone-treated mice.
Fig 5. Effects of TGF-β1, or ET-1, or TGF-β1 plus ET-1 on the expression of TGF-β isoforms in murine
lungmicrovascular endothelial cells.Murine lung microvascular endothelial cells were treated with either
TGF-β1, or ET-1, or Bosentan, or with TGF-β1 plus ET-1, or TGF-β1 plus ET-1 plus Bosentan for 72 h.
Expression levels of Tgfb1(A), Tgfb2 (B) and Tgfb3 (C) were determined by semiquantitative RT-PCR.
Values represent the mean (+/- standard deviation) expression levels of three replicates of three separate
experiments. C(t) values were normalized withGapdh. The saline control levels were arbitrarily set at 100%
expression. Values for other samples are expressed relative to the saline control. Statistical significance was
determined by Student’s two-tailed t test. **: p < 0.01; ***: p<0.001.
doi:10.1371/journal.pone.0161988.g005
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Coexpression of α-SMA and vWF in Perivascular Cells in the Lungs of
Mice Treated with Either Saline, or TGF-β1, or ET-1 or TGF-β1 Plus ET-1
Immunofluorescence staining of paraffin-embedded sections of lungs from saline-treated con-
trol mice for the presence of α-SMA and vWF show clearly delineated expression of each of
these proteins with no detectable overlap of expression (Fig 8A). However, in mice treated with
TGF-β1 alone, the number of α-SMA-positive cells increased, particularly surrounding the
Fig 6. Effects of TGF-β1, or ET-1, or TGF-β1 plus ET-1 on the expression of TGF-β receptors in murine
lungmicrovascular endothelial cells.Murine lung microvascular endothelial cells were treated with either
TGF-β1, or ET-1, or Bosentan, or with TGF-β1 plus ET-1, or with TGF-β1 plus ET-1 plus Bosentan for 72 h.
Expression levels of Tgfbr1(A), Tgfbr2 (B) and Tgfbr3 (C) were determined by semiquantitative RT-PCR.
Values represent the mean (+/- standard deviation) expression levels of three replicates of three separate
experiments. C(t) values were normalized withGapdh. The saline control levels were arbitrarily set at 100%
expression. Values for other samples are expressed relative to the saline control. Statistical significance was
determined by Student’s two-tailed t test.*: p<0.05; **: p < 0.01; ***: p<0.001.
doi:10.1371/journal.pone.0161988.g006
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small vessels in the lung (Fig 8B). Interestingly, a small percentage of vWF positive cells simul-
taneously displayed the expression of α-SMA surrounding these vessels suggesting that a cer-
tain proportion of these cells could be undergoing endothelial-to-mesenchymal transition
(white arrows). In lungs from animals treated with ET-1 alone, an increased number of α-
SMA-positive cells was observed compared to control animals, however, this increase was less
than that observed in animals treated with TGF-β1 alone (Fig 8C). In the animals treated with
both TGF-β1 plus ET-1, a massive increase in cells positive for α-SMA as well as for cells co-
staining for vWF and α-SMA (white arrows) was observed (Fig 8A).
Discussion
Activated myofibroblasts are considered the crucial effector cells in the development of patho-
logic tissue fibrosis. Given their important role during normal tissue repair reactions as well as
Fig 7. Histopathology of skin and lung isolated frommice treated with either saline, or TGF-β1, or ET-1 or TGF-
β1plus ET-1. Trichrome stained sections of skin and lungs frommice implanted subcutaneously with osmotic pumps
delivering either saline (left column), or 2.5 μg TGF-β1 (middle column), or 5 μg ET-1, or 2.5 μg TGF-β1+5 μg ET-1 during a
28 day period are shown. Skin samples (upper row) Magnification: 20X. Black boxes in the low power (10X images in the top
row are shown at 20X magnification to demonstrate changes in blood vessel (black arrows) morphology). Black boxes in the
low power (4X) images of lungs in the third row are displayed at higher magnification (10X) in the bottom row. Note the
replacement of alveolar structure with areas of fibrotic tissue consolidation in the lungs and the marked increase in collagen
deposition in the skin and lungs from TGF-β1-treated mice and noticeable greater increase in samples frommice receiving
both TGF-β1 plus ET-1. The samples frommice receiving only ET-1 show only a minimal increase in tissue collagen
accumulation.
doi:10.1371/journal.pone.0161988.g007
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in pathologic fibrogenesis there has been intense investigation aimed at the identification if
their origins [3,4]. Recently, EndoMT has been recognized as an important source for the gen-
eration of activated myofibroblasts in various animal models of tissue fibrosis and in several
human fibrotic diseases [13–15]. EndoMT is a complex biological process leading to the transi-
tion of an endothelial cell phenotype into the phenotype of mesenchymal cells with the initia-
tion of expression of α-SMA and the upregulated expression of fibrotic tissue components
including the fibrillar type I and type III collagens. TGF-β plays a crucial role in the induction
and regulation of EndoMT, both during embryonic development [12], as well as in animal
models of organ-specific fibrosis, and in various human fibrotic diseases [16–26]. Although
numerous studies have described important pro-fibrotic effects of ET-1 [40–46], the possibility
that ET-1 may contribute to EndoMT has not been extensively studied.
The results described here show that ET-1 enhanced the TGF-β1-mediated EndoMT pro-
cess resulting in potent stimulation of the expression of multiple mesenchymal cell-specific
genes including Acta2/α-SMA (Fig 2), the interstitial collagens Col1a1 and Col3a1 (Fig 3B and
3C), and relevant transcriptional coactivators such as Snai1 and Twist1 (Fig 4) in murine lung
microvascular endothelial cells. The Snail and Twist transcription factors are well character-
ized regulators of mesenchymal identity and also play a role in EndoMT during embryonic
development as well as in pathologic fibrotic conditions like cancer [56,57] Most intriguingly,
the results also demonstrate that ET-1 was able to induce a potent increase in the expression
of TGF-β1 and TGF-β2 (Fig 5) and of the three TGF-β receptors (Fig 6). It is plausible that the
ET-1 mediated upregulation of TGF-β receptors may result in increased sensitivity of these
cells to the TGF-β present in the microenvironment. Furthermore, ET-1 may be capable of
initiating an autocrine loop by inducing expression of the TGF-β ligands resulting in amplifi-
cation of the induction of EndoMT. It has previously been reported that in fibroblasts co-cul-
tured with keratinocytes, mechanical stress induces the expression of ET-1 in these fibroblasts
which can then augment the effects of TGF-β in triggering their transdifferentiaton into acti-
vated myofibroblasts with upregulated expression of α-SMA [58] and that the formation of
stress fibers was an early event in this process that was required for myofibroblast transdiffer-
entiation. We did not observe the formation of stress fibers during our experiment despite the
occurrence of EndoMT, however, it is possible that the sequence and kinetics of the events
involved in the transdifferentiation of quiescent fibroblasts to activated myofibroblasts may
Fig 8. Coexpression of vWF and α-SMA in small vessels of the lungs frommice treated with either saline, or TGF-β1,
or ET-1 or TGF-β1 plus ET-1.Confocal microscopy staining for vWF (red) and α-SMA (green) in the lungs frommice treated
with saline (A), TGF-β1 (B), ET-1 (C), or TGF-β1 + ET-1 (D). DAPI was used for counterstaining of nuclei. Endothelial cells
expressing vWF (red) are seen lining the large and small vessels of the lung. Activated myofibroblasts expressing α-SMA
(green) are seen surrounding the vessels and in the interstitium. Cells co-staining for vWF and α-SMA (yellow; white arrows)
in the small vessels represent cells in the process of endothelial-to-mesenchymal transition are observed in the TGF-β1 (B),
ET-1 (C), or TGF-β1 + ET-1 (D)-treated animals. No double positive cells were observed in lungs frommice injected with
saline (A). Magnification: 40X.
doi:10.1371/journal.pone.0161988.g008
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differ from those required for the transition of endothelial lineage cells to activated myofibro-
blasts (Fig 8).
These in vitro observations were confirmed by in vivo studies in mice that had received con-
tinuous administration of either TGF-β1 alone, ET-1 alone, or the combination of TGF-β1
plus ET-1 as shown in Figs 7, 8 and 9. In mice treated with TGF-β1 alone, an increase in dermal
thickness with fibrotic tissue accumulation in the dermis and surrounding the subdermal ves-
sels was observed. An accumulation of interstitial, peribronchial and perivascular collagen in
the lungs was also noted in response to TGF-β1. Only a minor increase in dermal or lung colla-
gen was observed in mice treated with ET-1 alone. However, the fibrotic changes in skin and
lung tissue histology observed in mice treated with TGF-β1 were accentuated in tissues from
mice that had been treated with the combination of TGF-β1 plus ET-1 (Fig 7). Costaining the
lungs with antibodies for the endothelial lineage marker vWF and for the marker of activated
myofibroblasts, α-SMA indicated that a small number of cells undergo EndoMT in mice
treated with either TGF-β1 or ET-1 alone but that treatment with TGF-β1 plus ET-1 greatly
increases the number of cells undergoing EndoMT to produce activated myofibroblasts.
A quantitative assessment of the collagen content demonstrated significant increases in
both skin and lung tissues from mice receiving TGF-β1 whereas less but still significant
Fig 9. Collagen content of skin and lung isolated frommice treated with either saline, or TGF-β1, or ET-1, or TGF-β1
plus ET-1.Hydroxyproline assay of collagen content of skin isolated from the delivery site of the subcutaneous pumps (A)
and of the lungs (B) are displayed. One sample of skin and one sample of lung tissue from each experimental condition were
hydrolyzed and aliquots of the hydrolysates were assayed for their hydroxyproline content. Results are shown as the
mean μg of collagen /mg of wet weight of three aliquots from the same hydrolyzed tissue sample. Statistical significance was
determined by Student’s two-tailed t test.*: p<0.05; **: p < 0.01; ***: p<0.001.
doi:10.1371/journal.pone.0161988.g009
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Fig 10. Diagrammatic representation of a proposed autocrine pathway of the stimulation of TGF-β-
mediated EndoMT by ET-1. Following TGF-β dimerization and dimer binding to its cognate cell surface
receptor there is activation of the TGF-β receptor 2 which in turn leads to phosphorylation of the TGF-β
receptor 1. The phosphorylated TGF-β1 induces the phosphorylation of Smad2/3, the recruitment of Smad4,
and the translocation of the complex to the nucleus. Binding of Smads to specific gene promoter elements
results in the induction of increased transcription of TGF-β1 target genes (indicated by solid red arrows).
When exposed to TGF-β alone, endothelial cells undergo EndoMT, resulting in increased expression and
production of Acta2/α-SMAmediated by the increased levels of mesenchymal-specific transcription factors
Snail1, Snail2 and Twist1. The phenotypic transition of endothelial cells to activated myofibroblasts is
responsible for vascular and tissue fibrosis. Exposure of endothelial cells to ET-1 plus TGF-β synergistically
induces increased expression of TGF-β and its receptors (indicated by red broken arrows) with the increased
production of the corresponding proteins generating an autocrine loop that maintains and amplifies the
EndoMT-inducing effects of TGF-β resulting in progressive tissue fibrosis.
doi:10.1371/journal.pone.0161988.g010
ET-1 Stimulates TGF-β1-Induced EndoMT
PLOSONE | DOI:10.1371/journal.pone.0161988 September 1, 2016 17 / 21
increases in tissue morphology or collagen content were observed in the skin and lungs of mice
treated with ET-1 alone (Fig 8). However, the combined treatment with TGF-β1 plus ET-1
resulted in a significantly greater increase in collagen content compared to that of tissues from
animals receiving only TGF-β1.
The results described here indicate that ET-1 potentiates the TGF-β1-mediated acquisition
of a mesenchymal cell phenotype by lung endothelial cells as well as the exaggerated tissue
fibrotic process induced by TGF-β1. These observations identify a novel mechanism for ET-1
participation in the development of tissue fibrosis and proliferative vasculopathy mediated
through the potentiation of TGF-β-induced EndoMT. Furthermore, the assessment of gene
expression levels of TGF-β isoforms and of their corresponding receptors described here sug-
gest that in the lung microvascular endothelial cells ET-1 produced by these cells may initiate a
profibrotic autocrine pathway. In this pathway, ET-1 stimulates the expression of TGF-β1 and
TGF-β2 (Fig 5A and 5B), and induces a parallel stimulation of the expression of the TGF-β
receptors (Fig 6), thus, creating a potent autocrine mechanism of activation of TGF-β-induced
EndoMT resulting in strong pro-fibrotic effects as illustrated diagrammatically in Fig 10. These
data provide a novel mechanistic interaction between TGF-β and ET-1 and support the con-
cept that ET-1 may play an important pathogenetic role during the earliest stages of develop-
ment of fibrotic processes involving TGF-β-mediated EndoMT. These results also expand the
previously described interactions between TGF-β and ET-1 during normal tissue repair reac-
tions or in the course of organ-specific or systemic pathologic fibrogenesis [59–64].
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